Ensemble is the first company to successfully and reliably exploit synthetic macrocycle drugs, called Ensemblins™. With their distinctive macrocyclic ring structure, Ensemblins have unique properties to address difficult-to-address drug targets that are known to play key roles in disease processes, yet are currently undruggable with conventional small molecule drugs. With their unique chemical and biological properties, Ensemblins are a new class of drugs in the emerging therapeutic space between small molecules and biologics.Ensemble's leadership capabilities in developing macrocycle drugs are based on the company's proprietary, DNA-programmed chemistry drug discovery platform. The company has a pipeline of proprietary and partnered Ensemblin drug candidates to treat a broad range of diseases, including inflammation, oncology and diabetes.